Lysosomal Storage · Sphingolipids · Biomarkers
One missing acid enzyme backs up its substrate — but lipids never accumulate alone. Gangliosides, cholesterol, and BMP pile up as secondary storage. The lyso-lipid biomarkers, and which diseases we can treat versus only measure.
12 min
Brain Lipid Metabolism · Nature Cell Biology
Every cell type in the brain runs a distinct lipid economy. A landmark review maps astrocytes, neurons, microglia, and oligodendrocytes — with immediate implications for neurodegeneration.
15 min
GLP-1 · Alzheimer's · NLRP3
Semaglutide failed EVOKE. Liraglutide reduced brain volume loss 50% in ELAD. Real-world data shows 40–50% dementia risk reduction. The mechanism is neuroinflammation — not weight loss.
13 min
Ketone Bodies · BHB Signaling
The Alzheimer's brain stops using glucose efficiently — measurable two decades before symptoms. BHB bypasses this block, suppresses NLRP3, and activates neuroprotective gene programs.
13 min
DHA · Membrane Biology · APOE4
Up to 40% of synaptic membrane fatty acids are DHA. It is not a supplement — it is the structural lipid that makes rapid, reliable synaptic transmission physically possible.
12 min
Multiple Sclerosis · Nature Neuroscience
Lipid-laden GPNMB+ microglia producing oxylipins drive chronic lesion expansion in secondary progressive MS. MAGL inhibition rescues lesion recovery. CSF oxylipins as biomarkers.
14 min
Myelin · Alzheimer's · Bartzokis
George Bartzokis proposed that Alzheimer's begins not with amyloid but with the slow unraveling of myelin. Two decades later, the evidence keeps piling up on his side.
9 min
Lipid Genetics · APOE4 · TREM2 · GBA
APOE4, TREM2, GBA — the genes carrying highest risk for Alzheimer's and Parkinson's disproportionately encode lipid enzymes and transporters. Lipid dysregulation is upstream.
9 min
APOE4 · Alzheimer's & Atherosclerosis
One gene. Two organs. One lipid biology. APOE4 drives neurodegeneration and vascular disease simultaneously through impaired cholesterol transport and defective membrane lipid delivery.
9 min
Parkinson's · Lysosomes · GBA1 · LRRK2
GBA1, LRRK2, GRN, C9orf72 — every major genetic risk for Parkinson's and FTD converges on the same organelle. Lysosomal lipid trafficking failure is the mechanism, not the consequence.
10 min
Endocannabinoids · FAAH · MAGL
Anandamide, 2-AG, OEA, PEA — lipid signals synthesized on demand from membrane phospholipids. FAAH and MAGL are the therapeutic targets. The complete endocannabinoid biology.
11 min
Membrane Disease · Ceramide · Plasmalogen
Ceramide accumulation, plasmalogen depletion, neuroferroptosis, DHA deficiency — four lipid failure modes converging on the same vulnerable membranes across AD, PD, ALS, and MS.
11 min
Parkinson's · Sphingolipid Biomarkers
BMP in urine tracks LRRK2 kinase activity. GluSph in plasma tracks GBA1 dysfunction. The first lipid-based precision biomarker framework for Parkinson's stratification.
9 min
Omega-3 · Meningeal Lymphatics
Long-term DHA supplementation preserves the meningeal lymphatic system — reducing tau and amyloid accumulation a decade before symptoms. A new explanation for fish oil and brain aging.
8 min
Liver–Brain Axis · DHA · Plasmalogens
DHA, plasmalogens, endocannabinoids — the brain's critical lipids are manufactured in the liver, gut, and periphery. When those supply chains fail, neurodegeneration follows.
12 min
Diagnostics · p-Tau217 · JAMA 2025
Plasma p-tau217 detects Alzheimer's pathology with AUC 0.93–0.96 from a standard blood draw — 10–15 years before symptoms. Mass spectrometry made it possible.
10 min
Anandamide · Alzheimer's
Anandamide — your brain's natural cannabis-like lipid — is significantly reduced in Alzheimer's disease. Here's what that means and where the research is heading.
5 min
Liver–Brain Axis · DHA · Personal
The DHA in your brain didn't swim there from your last salmon dinner. Your liver made it — and when that process breaks down, your brain feels it decades later.
7 min